Metamizol Noridem

Metamizole, the active ingredient in Metamizol Noridem, is a pyrazolone presented as a sterile injectable solution for intramuscular and intravenous use. It provides analgesic and antipyretic effects for patients experiencing pain or fever. GNH USA supplies Metamizol Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metamizol Noridem is a pyrazolone analgesic and antipyretic used in acute pain and fever management. - Pain: provides rapid analgesic relief in moderate to severe acute pain. - Fever: reduces elevated body temperature in febrile conditions. - Post‑operative pain: helps control pain after surgical procedures.

Metamizol Noridem may cause a range of adverse reactions.

Common Side Effects: - Hypotension: transient drop in blood pressure after injection. - Nausea or vomiting: gastrointestinal upset following administration. - Injection‑site pain or mild rash: local irritation at the site of administration.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white‑blood‑cell count, potentially life‑threatening. - Anaphylaxis or severe allergic reactions: rapid onset of hives, swelling, and respiratory distress. - Stevens‑Johnson syndrome or other severe skin reactions: extensive blistering and mucosal involvement.

Metamizol Noridem should be used with careful clinical oversight. - Renal function assessment: evaluate kidney status before initiating therapy. - Blood‑count monitoring: perform regular hematology tests to detect early signs of agranulocytosis. - Hypersensitivity caution: avoid in patients with known allergy to pyrazolones. - Liver disease consideration: use only under supervision in severe hepatic impairment. - Medical supervision: administer only by qualified healthcare professionals. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Metamizol Noridem can interact with several drug classes.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: may amplify risk of agranulocytosis. - Other NSAIDs or pyrazolones: increase potential for blood‑disorder toxicity. - Drugs known to cause severe hypersensitivity (e.g., carbamazepine): heightened allergic risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency. - ACE inhibitors or ARBs: can potentiate hypotensive effects. - Loop diuretics: may affect renal clearance and electrolyte balance.